We are developing a multi-kinase inhibitor that inhibits various protein kinases, chiefly leucine-rich repeat kinase 2 (LRRK2), for the treatment of glaucoma and ocular hypertension.
Animal studies and other tests have confirmed that this pipeline drug has the effect of lowering intraocular pressure.
We believe its strong effectiveness in lowering intraocular pressure is attributed to its new mechanism of action.

In 2018, we carried out in-house Phase I/IIa clinical trials in the U.S.
For DWTI, which has typically focused on basic research, this was our first foray into clinical development. We are currently preparing for late-stage Phase II clinical trials.

In addition, in efforts to expand indications for the drug, we have confirmed its effects on pulmonary hypertension in animal studies etc. We are hopeful of being able to create new possibilities for H-1337.

in U.S.
Clinical indication Glaucoma and ocular hypertension
Development process Phase I/IIa clinical trials (U.S.) completed (clinical POC obtained)
Licensee Developed internally

Development Progress

  • 2021.04
    Announced development plan in medium-term management plan in Japanese
  • 2018.09
    Phase I/IIa clinical trials (U.S.) completed
  • 2018.03
    Phase I/IIa clinical trials (U.S.) started
  • 2016.04
    Non-clinical studies started